Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
& Karami-Mohajeri, S
2002 May-Jun;9(3):225-33
In a phase 2 clinical trial conducted on an obese population, over a 26-week period, patients who were administered a dose range of efinopegdutide from 5 mg to 10 mg experienced a weight reduction of up to 11.8%
The ADA standard for the treatment of diabetes updated in 2020 indicated that patients with T2DM diagnosed with CVD or those with CVD risk factors can use GLP-1RAs and SGLT2 inhibitors with evidence of cardiovascular benefits to reduce cardiovascular risk, regardless of HbA1c levels or individualized HbA1c control objectives [189]
In addition, some of the minimal literature available suggests that the presence of GI symptoms (specifically nausea, vomiting, bloating or abdominal pain) dramatically increases the likelihood of there being residual gastric contents
Where to inject: The back or outer portion of the upper arm, in the fatty area between your shoulder and elbow
